IRIS
FERRERI, ANDRES JOSE MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.991
AS - Asia 7.923
EU - Europa 7.229
SA - Sud America 2.053
Continente sconosciuto - Info sul continente non disponibili 378
AF - Africa 161
OC - Oceania 20
Totale 25.755
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.454
RU - Federazione Russa 3.943
SG - Singapore 2.806
CN - Cina 2.286
BR - Brasile 1.641
IT - Italia 1.280
HK - Hong Kong 1.083
VN - Vietnam 760
SE - Svezia 634
FR - Francia 381
BD - Bangladesh 313
DE - Germania 266
CA - Canada 252
GB - Regno Unito 229
AR - Argentina 149
IN - India 130
FI - Finlandia 126
MX - Messico 91
ID - Indonesia 89
EC - Ecuador 83
AT - Austria 71
JP - Giappone 63
NL - Olanda 52
CO - Colombia 50
TR - Turchia 49
IQ - Iraq 48
ZA - Sudafrica 48
PL - Polonia 39
PY - Paraguay 37
ES - Italia 36
IE - Irlanda 35
JM - Giamaica 32
SA - Arabia Saudita 31
CL - Cile 29
CR - Costa Rica 29
UA - Ucraina 29
VE - Venezuela 29
EG - Egitto 27
MY - Malesia 26
NI - Nicaragua 22
PK - Pakistan 22
MA - Marocco 21
PE - Perù 21
UZ - Uzbekistan 21
NP - Nepal 19
HN - Honduras 18
TH - Thailandia 18
AE - Emirati Arabi Uniti 17
KR - Corea 17
PT - Portogallo 17
AU - Australia 16
GT - Guatemala 16
IR - Iran 16
KE - Kenya 16
LT - Lituania 14
PH - Filippine 14
SV - El Salvador 14
TN - Tunisia 14
IL - Israele 12
JO - Giordania 12
TT - Trinidad e Tobago 12
PR - Porto Rico 11
RO - Romania 11
BB - Barbados 8
KZ - Kazakistan 8
UY - Uruguay 8
CH - Svizzera 7
DZ - Algeria 7
PS - Palestinian Territory 7
TW - Taiwan 7
AL - Albania 6
BO - Bolivia 6
LB - Libano 6
SY - Repubblica araba siriana 6
AZ - Azerbaigian 5
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
GG - Guernsey 5
GP - Guadalupe 5
HR - Croazia 5
NO - Norvegia 5
OM - Oman 5
SC - Seychelles 5
YE - Yemen 5
BG - Bulgaria 4
BS - Bahamas 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
KW - Kuwait 4
MD - Moldavia 4
NG - Nigeria 4
PA - Panama 4
RS - Serbia 4
AM - Armenia 3
BE - Belgio 3
GR - Grecia 3
HT - Haiti 3
LV - Lettonia 3
MM - Myanmar 3
Totale 25.331
Salva come PNG Salva come JPEG
Città #
Singapore 1.298
Hong Kong 1.076
Ashburn 986
Dallas 901
Moscow 845
San Jose 765
Council Bluffs 417
Shanghai 388
Hefei 345
Milan 326
Lauterbourg 298
Ho Chi Minh City 288
Princeton 276
Lawrence 270
Beijing 252
New York 244
Santa Clara 216
Phoenix 170
Los Angeles 155
Hanoi 142
São Paulo 136
Rome 95
Helsinki 85
Nuremberg 84
Miano 65
Montreal 57
Orem 55
Munich 52
Toronto 52
Chicago 49
Belo Horizonte 48
Naples 48
Atlanta 47
Brooklyn 47
Rio de Janeiro 46
Guangzhou 45
Buffalo 38
Tokyo 38
Chennai 36
Boston 35
Houston 35
Miami 35
Dublin 34
Seattle 34
London 33
North Bergen 33
Haiphong 32
Mexico City 32
Boardman 31
The Dalles 31
Da Nang 30
Turku 30
Biên Hòa 29
Brasília 29
Vienna 29
Warsaw 29
Washington 28
Denver 27
Johannesburg 27
Poplar 26
Guayaquil 25
Porto Alegre 25
Mumbai 24
Omaha 24
Quito 24
Stockholm 24
Hangzhou 23
Asunción 22
Florence 21
Managua 21
Manchester 21
Frankfurt am Main 20
Jakarta 20
Tashkent 20
San Francisco 19
Campinas 18
Kingston 18
Leicester 18
San José 18
Sorocaba 18
Amsterdam 17
Columbus 17
Jacksonville 17
Kuala Lumpur 17
Osasco 17
Thái Bình 17
Tianjin 17
Turin 17
Baghdad 16
Brescia 16
Charlotte 16
Detroit 16
Goiânia 16
Bologna 15
Curitiba 15
Las Vegas 15
Nairobi 15
Santiago 15
Shenzhen 15
St Louis 15
Totale 12.174
Salva come PNG Salva come JPEG
Nome #
Definition, diagnosis, and management of intravascular large B-Cell lymphoma: Proposals and perspectives from an international consensus meeting 414
How we treat primary central nervous system lymphoma 246
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 224
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 211
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 196
Radiomics-Based Machine Learning Model for Predicting Overall and Progression-Free Survival in Rare Cancer: A Case Study for Primary CNS Lymphoma Patients 178
A multicenter study of treatment of primary CNS lymphoma 176
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial 162
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 162
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome 160
THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK 154
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review 145
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 142
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 140
Chronic lymphocytic leukaemia 139
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) 138
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 131
Central nervous system marginal zone B-cell lymphoma associated with chlamydophila psittaci infection 127
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 127
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals 126
SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS WITH BURKITT LYMHOMA 125
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi 121
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial 120
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 120
Primary central nervous system lymphoma 120
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type 119
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 118
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness 117
ORBIT IRRADIATION AS SALVAGE TREATMENT FOR PATIENTS WITH OCULAR ADNEXAL MALT LYMPHOMA (OAML) RELAPSED AFTER OR REFRACTORY TO CHLAMYDIA PSITTACI-ERADICATING ANTIBIOTIC THERAPY 116
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 115
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma 115
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 114
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) 114
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells 114
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to Chlamydia psittaci Eradication 114
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents 110
Chronic lymphocytic leukemia 110
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma 110
Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study). 110
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial 110
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type 108
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL 108
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study 106
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) 106
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 105
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 104
Prevention and management of secondary central nervous system lymphoma 104
The impact of histopathologic diagnosis on the proper management of testis neoplasms 103
Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type 103
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 102
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). 102
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 102
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy 101
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis 100
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma 100
FEASIBILITY AND EFFICACY OF CHLAMYDIA PSITTACI ERADICATION WITH PROLONGED DOXYCYCLINE THERAPY IN LOCALIZED OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL): 7-YEAR RESULTS OF THE IELSG39 MULTICENTER TRIAL 99
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial 98
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center 98
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 98
Therapeutic management of refractory or relapsed primary central nervous system lymphomas 98
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 97
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 97
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 97
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas 97
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy 96
Gamma-delta t-cell lymphomas 95
A retrospective series of upfront therapy in primary brain lymphomas 95
Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma 94
Chlamydia infection and lymphoma: Multiple detection methods highlight an association beyond lymphomas of the ocular adnexa 93
New hopes in relapsed refractory primary central nervous system lymphoma 92
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 88
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 88
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 88
Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring 87
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 87
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy 86
Primary cardiac lymphoma in immunocompetent patients - Diagnostic and therapeutic management 86
Lymphoblastic lymphoma 86
Mantle cell lymphoma 85
Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis 84
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study 84
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma 83
Cyclin D3 immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27(KIP1) IR prognostic role in primary gastric lymphomas (PGL). 83
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 82
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53 82
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial 81
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 81
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial 81
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 79
Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate 79
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms 78
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) 78
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 78
Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas 78
Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods 78
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial 77
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 77
Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL) 77
Breaching the blood–brain tumor barrier for tumor therapy 77
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients 77
Totale 11.263
Salva come PNG Salva come JPEG
Categoria #
all - tutte 153.996
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 153.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022230 0 0 0 71 9 6 16 91 4 5 1 27
2022/20231.341 631 271 56 6 9 135 42 86 53 10 17 25
2023/2024899 39 36 42 58 238 123 57 67 36 52 47 104
2024/20254.272 560 63 44 124 134 340 451 307 859 776 275 339
2025/202614.407 912 1.187 1.279 2.134 1.027 318 1.239 939 3.655 717 378 622
2026/20274.548 793 1.259 886 1.610 0 0 0 0 0 0 0 0
Totale 25.755